Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Identifieur interne : 001413 ( PubMed/Corpus ); précédent : 001412; suivant : 001414Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Auteurs : Amandine Legat ; Hélène Maby-El Hajjami ; Petra Baumgaertner ; Laurène Cagnon ; Samia Abed Maillard ; Christine Geldhof ; Emanuela M. Iancu ; Luc Lebon ; Philippe Guillaume ; Danijel Dojcinovic ; Olivier Michielin ; Emanuela Romano ; Grégoire Berthod ; Donata Rimoldi ; Frédéric Triebel ; Immanuel Luescher ; Nathalie Rufer ; Daniel E. SpeiserSource :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.
English descriptors
- KwdEn :
- Antigens, CD (chemistry), Antigens, CD (immunology), Antigens, Neoplasm (immunology), Biomarkers, CD4-Positive T-Lymphocytes (immunology), CD4-Positive T-Lymphocytes (metabolism), CD8-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (metabolism), Cancer Vaccines (administration & dosage), Cancer Vaccines (adverse effects), Cancer Vaccines (immunology), Combined Modality Therapy, Female, Humans, Lymphocyte Count, MART-1 Antigen (immunology), Male, Melanoma (immunology), Melanoma (pathology), Melanoma (therapy), Peptides (immunology), Treatment Outcome, Vaccination.
- MESH :
- chemical , administration & dosage : Cancer Vaccines.
- chemical , adverse effects : Cancer Vaccines.
- chemical , chemistry : Antigens, CD.
- chemical , immunology : Antigens, CD, Antigens, Neoplasm, Cancer Vaccines, MART-1 Antigen, Peptides.
- chemical : Biomarkers.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Melanoma.
- metabolism : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes.
- pathology : Melanoma.
- therapy : Melanoma.
- Combined Modality Therapy, Female, Humans, Lymphocyte Count, Male, Treatment Outcome, Vaccination.
Abstract
Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses.
DOI: 10.1158/1078-0432.CCR-15-1212
PubMed: 26500235
Links to Exploration step
pubmed:26500235Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.</title><author><name sortKey="Legat, Amandine" sort="Legat, Amandine" uniqKey="Legat A" first="Amandine" last="Legat">Amandine Legat</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Maby El Hajjami, Helene" sort="Maby El Hajjami, Helene" uniqKey="Maby El Hajjami H" first="Hélène" last="Maby-El Hajjami">Hélène Maby-El Hajjami</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Baumgaertner, Petra" sort="Baumgaertner, Petra" uniqKey="Baumgaertner P" first="Petra" last="Baumgaertner">Petra Baumgaertner</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cagnon, Laurene" sort="Cagnon, Laurene" uniqKey="Cagnon L" first="Laurène" last="Cagnon">Laurène Cagnon</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Abed Maillard, Samia" sort="Abed Maillard, Samia" uniqKey="Abed Maillard S" first="Samia" last="Abed Maillard">Samia Abed Maillard</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Geldhof, Christine" sort="Geldhof, Christine" uniqKey="Geldhof C" first="Christine" last="Geldhof">Christine Geldhof</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Iancu, Emanuela M" sort="Iancu, Emanuela M" uniqKey="Iancu E" first="Emanuela M" last="Iancu">Emanuela M. Iancu</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Lebon, Luc" sort="Lebon, Luc" uniqKey="Lebon L" first="Luc" last="Lebon">Luc Lebon</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Guillaume, Philippe" sort="Guillaume, Philippe" uniqKey="Guillaume P" first="Philippe" last="Guillaume">Philippe Guillaume</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Dojcinovic, Danijel" sort="Dojcinovic, Danijel" uniqKey="Dojcinovic D" first="Danijel" last="Dojcinovic">Danijel Dojcinovic</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Michielin, Olivier" sort="Michielin, Olivier" uniqKey="Michielin O" first="Olivier" last="Michielin">Olivier Michielin</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Romano, Emanuela" sort="Romano, Emanuela" uniqKey="Romano E" first="Emanuela" last="Romano">Emanuela Romano</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Berthod, Gregoire" sort="Berthod, Gregoire" uniqKey="Berthod G" first="Grégoire" last="Berthod">Grégoire Berthod</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Rimoldi, Donata" sort="Rimoldi, Donata" uniqKey="Rimoldi D" first="Donata" last="Rimoldi">Donata Rimoldi</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Triebel, Frederic" sort="Triebel, Frederic" uniqKey="Triebel F" first="Frédéric" last="Triebel">Frédéric Triebel</name><affiliation><nlm:affiliation>Immutep, SA, Orsay, France.</nlm:affiliation></affiliation></author><author><name sortKey="Luescher, Immanuel" sort="Luescher, Immanuel" uniqKey="Luescher I" first="Immanuel" last="Luescher">Immanuel Luescher</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Rufer, Nathalie" sort="Rufer, Nathalie" uniqKey="Rufer N" first="Nathalie" last="Rufer">Nathalie Rufer</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E" last="Speiser">Daniel E. Speiser</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26500235</idno><idno type="pmid">26500235</idno><idno type="doi">10.1158/1078-0432.CCR-15-1212</idno><idno type="wicri:Area/PubMed/Corpus">001413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001413</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.</title><author><name sortKey="Legat, Amandine" sort="Legat, Amandine" uniqKey="Legat A" first="Amandine" last="Legat">Amandine Legat</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Maby El Hajjami, Helene" sort="Maby El Hajjami, Helene" uniqKey="Maby El Hajjami H" first="Hélène" last="Maby-El Hajjami">Hélène Maby-El Hajjami</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Baumgaertner, Petra" sort="Baumgaertner, Petra" uniqKey="Baumgaertner P" first="Petra" last="Baumgaertner">Petra Baumgaertner</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Cagnon, Laurene" sort="Cagnon, Laurene" uniqKey="Cagnon L" first="Laurène" last="Cagnon">Laurène Cagnon</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Abed Maillard, Samia" sort="Abed Maillard, Samia" uniqKey="Abed Maillard S" first="Samia" last="Abed Maillard">Samia Abed Maillard</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Geldhof, Christine" sort="Geldhof, Christine" uniqKey="Geldhof C" first="Christine" last="Geldhof">Christine Geldhof</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Iancu, Emanuela M" sort="Iancu, Emanuela M" uniqKey="Iancu E" first="Emanuela M" last="Iancu">Emanuela M. Iancu</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Lebon, Luc" sort="Lebon, Luc" uniqKey="Lebon L" first="Luc" last="Lebon">Luc Lebon</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Guillaume, Philippe" sort="Guillaume, Philippe" uniqKey="Guillaume P" first="Philippe" last="Guillaume">Philippe Guillaume</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Dojcinovic, Danijel" sort="Dojcinovic, Danijel" uniqKey="Dojcinovic D" first="Danijel" last="Dojcinovic">Danijel Dojcinovic</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Michielin, Olivier" sort="Michielin, Olivier" uniqKey="Michielin O" first="Olivier" last="Michielin">Olivier Michielin</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Romano, Emanuela" sort="Romano, Emanuela" uniqKey="Romano E" first="Emanuela" last="Romano">Emanuela Romano</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Berthod, Gregoire" sort="Berthod, Gregoire" uniqKey="Berthod G" first="Grégoire" last="Berthod">Grégoire Berthod</name><affiliation><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Rimoldi, Donata" sort="Rimoldi, Donata" uniqKey="Rimoldi D" first="Donata" last="Rimoldi">Donata Rimoldi</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Triebel, Frederic" sort="Triebel, Frederic" uniqKey="Triebel F" first="Frédéric" last="Triebel">Frédéric Triebel</name><affiliation><nlm:affiliation>Immutep, SA, Orsay, France.</nlm:affiliation></affiliation></author><author><name sortKey="Luescher, Immanuel" sort="Luescher, Immanuel" uniqKey="Luescher I" first="Immanuel" last="Luescher">Immanuel Luescher</name><affiliation><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Rufer, Nathalie" sort="Rufer, Nathalie" uniqKey="Rufer N" first="Nathalie" last="Rufer">Nathalie Rufer</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E" last="Speiser">Daniel E. Speiser</name><affiliation><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigens, CD (chemistry)</term><term>Antigens, CD (immunology)</term><term>Antigens, Neoplasm (immunology)</term><term>Biomarkers</term><term>CD4-Positive T-Lymphocytes (immunology)</term><term>CD4-Positive T-Lymphocytes (metabolism)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>CD8-Positive T-Lymphocytes (metabolism)</term><term>Cancer Vaccines (administration & dosage)</term><term>Cancer Vaccines (adverse effects)</term><term>Cancer Vaccines (immunology)</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>MART-1 Antigen (immunology)</term><term>Male</term><term>Melanoma (immunology)</term><term>Melanoma (pathology)</term><term>Melanoma (therapy)</term><term>Peptides (immunology)</term><term>Treatment Outcome</term><term>Vaccination</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, CD</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, CD</term><term>Antigens, Neoplasm</term><term>Cancer Vaccines</term><term>MART-1 Antigen</term><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term><term>CD8-Positive T-Lymphocytes</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term><term>CD8-Positive T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>Male</term><term>Treatment Outcome</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26500235</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation></Journal><ArticleTitle>Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.</ArticleTitle><Pagination><MedlinePgn>1330-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-1212</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Sixteen metastatic melanoma patients received serial vaccinations. Up to nine injections were subcutaneously administered in three cycles, each with three vaccinations every 3 weeks, with 6 to 14 weeks interval between cycles. Blood samples were collected at baseline, 1-week after the third, sixth and ninth vaccination, and 6 months after the last vaccination. Circulating T-cells were monitored by tetramer staining directly ex vivo, and by combinatorial tetramer and cytokine staining on in vitro stimulated cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Side effects were mild to moderate, comparable to vaccines with Montanide alone. Specific CD8 T-cell responses to at least one peptide formulated in the vaccine preparation were found in 13 of 16 patients. However, two of the four short peptides of the vaccine formulation did not elicit CD8 T-cell responses. Specific CD4 T-cell responses were found in all 16 patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We conclude that vaccination with IMP321 is a promising and safe strategy for inducing sustained immune responses, encouraging further development for cancer vaccines as components of combination therapies.</AbstractText><CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Legat</LastName><ForeName>Amandine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maby-El Hajjami</LastName><ForeName>Hélène</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgaertner</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cagnon</LastName><ForeName>Laurène</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abed Maillard</LastName><ForeName>Samia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geldhof</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iancu</LastName><ForeName>Emanuela M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebon</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillaume</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>TCMetrix, Epalinges, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dojcinovic</LastName><ForeName>Danijel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>TCMetrix, Epalinges, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michielin</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berthod</LastName><ForeName>Grégoire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rimoldi</LastName><ForeName>Donata</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triebel</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Immutep, SA, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luescher</LastName><ForeName>Immanuel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>TCMetrix, Epalinges, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rufer</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Speiser</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C076113">CD223 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019496">Cancer Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058965">MART-1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019496" MajorTopicYN="N">Cancer Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058965" MajorTopicYN="N">MART-1 Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26500235</ArticleId><ArticleId IdType="pii">1078-0432.CCR-15-1212</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1212</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001413 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001413 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26500235
|texte= Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26500235" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |